AbbVie Inc. ABBV, +1.94% on Friday reported fourth-quarter sales that topped analysts’ estimates, even as it faces low-cost competition for its top-selling drug, Humira. The drugmaker reported fourth-quarter net income of $822 million, or 46 cents per share, down sharply from$2.473 billion, or $1.38 per share, in the year-earlier period. Adjusted earnings per share of$2.79, which included an unfavorable impact of 15 cents a share related to acquired in-process research and development expenses, matched th ...